Current status of intracavitary chemotherapy

While the most effective treatment regimens and both short-term and long-term toxicities remain to be determined, it is not unreasonable for clinicians treating patients with minimal residual disease following cisplatin-based systemic chemotherapy for ovarian carcinoma to try cisplatin by the intraperitoneal route.